Product image of Norvir (Ritonavir) supplied by GNH India

Norvir

Active Ingredient:
Ritonavir
Origin:
EU

Norvir (Ritonavir)

Ritonavir, the active ingredient in Norvir, is a protease inhibitor presented as an oral dosage form for oral use. It treats HIV-1 infection in combination with other antiretroviral agents. It is used as part of highly active antiretroviral therapy (HAART) to suppress viral replication and improve immune function.

GNH India supplies Norvir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and oncology centres worldwide, adhering to EU quality standards and providing regulatory documentation, including detailed batch release certificates and stability data.

Manufacturer / TM Owner

Abbvie Deutschland Gmbh & Co. Kg

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ritonavir is a protease inhibitor used in the management of HIV-1 infection and related therapeutic strategies.

  • HIV-1 infection: used in combination with other antiretroviral agents to achieve viral suppression.
  • Protease inhibitor boosting: co‑administered to increase plasma concentrations of other protease inhibitors.
  • Treatment‑experienced HIV patients: incorporated into regimens for individuals with prior antiretroviral exposure to enhance efficacy.

How It Works

  • Ritonavir binds to the active site of the HIV‑1 protease enzyme, preventing the cleavage of viral polyprotein precursors into functional proteins required for viral maturation. This inhibition blocks the production of infectious virions. Additionally, ritonavir potently inhibits the cytochrome P450 3A4 isoenzyme, raising plasma levels of co‑administered protease inhibitors and enhancing their antiviral effect.

Side Effects

Ritonavir may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools occurring intermittently.
  • Fatigue: general feeling of tiredness.
  • Headache: mild to moderate cranial pain.
  • Rash: skin erythema or pruritus.
  • Taste alteration: dysgeusia or metallic taste.

Serious or Rare Side Effects

  • Hepatotoxicity: elevated liver enzymes or hepatitis.
  • Pancreatitis: inflammation of the pancreas with abdominal pain.
  • QT interval prolongation: cardiac conduction abnormalities.
  • Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome.
  • Hyperglycemia: significant rise in blood glucose levels.
  • Lipodystrophy: abnormal fat redistribution.

Precautions & Warnings

Before initiating ritonavir therapy, clinicians should consider several safety measures.

  • Liver monitoring: assess hepatic function regularly due to risk of hepatotoxicity.
  • Lipid assessment: evaluate cholesterol and triglyceride levels as dyslipidemia may occur.
  • Glucose surveillance: monitor blood glucose, especially in diabetic patients.
  • Hypersensitivity: avoid use in individuals with known ritonavir allergy.
  • Drug‑specific dosing: adjust concomitant protease inhibitor doses when required.
  • Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Ritonavir interacts with many medications through CYP3A4 inhibition, requiring careful management.

Major Interactions (Avoid)

  • Simvastatin: risk of severe myopathy and rhabdomyolysis.
  • Cisapride: can cause life‑threatening cardiac arrhythmias.
  • Ergot alkaloids: may precipitate ergotism with vasospasm.

Moderate Interactions (Monitor Closely)

  • Atorvastatin: may increase statin exposure; dose adjustment recommended.
  • Midazolam: enhanced sedation; consider dose reduction.
  • Rifampicin: strong CYP3A4 inducer that reduces ritonavir levels; avoid co‑administration.

Frequently Asked Questions

Norvir contains ritonavir, a protease inhibitor that is used as part of combination antiretroviral therapy for the treatment of HIV‑1 infection. It helps suppress viral replication when given together with other antiretroviral agents.

Ritonavir blocks the HIV‑1 protease enzyme, preventing the cleavage of viral polyproteins needed for mature virus formation. It also strongly inhibits the CYP3A4 enzyme, raising the plasma concentrations of co‑administered protease inhibitors and enhancing their antiviral activity.

The dosage of Norvir is individualized by the prescribing clinician based on the patient’s overall antiretroviral regimen, viral load, and tolerance. Only a qualified healthcare professional should determine the appropriate dose.

Safety data for ritonavir in pregnancy and lactation are limited. The decision to use Norvir during pregnancy or while breastfeeding should be made by a healthcare provider after weighing potential benefits against possible risks to the mother and infant.

To request Norvir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ritonavir is unique because, in addition to its antiviral activity, it is a potent CYP3A4 inhibitor used to boost the exposure of many other protease inhibitors. This pharmacokinetic advantage can simplify dosing but also requires careful management of drug‑drug interactions compared with agents that lack boosting properties.

Norvir should be stored at room temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperatures to maintain its stability and potency.

Norvir is taken orally, usually as a tablet, with or without food as directed by the prescribing clinician. The exact administration schedule depends on the overall antiretroviral regimen and should follow the healthcare provider’s instructions.

Serious risks include hepatotoxicity, pancreatitis, QT interval prolongation, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, hyperglycemia, and lipodystrophy. Patients should be monitored regularly for these adverse events, and any concerning symptoms should be reported promptly.

Norvir should be avoided in individuals with known hypersensitivity to ritonavir or any component of the formulation. Caution is also advised for patients with severe liver disease, uncontrolled cardiac arrhythmias, or those taking contraindicated medications that may lead to dangerous interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ritonavir

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT